Episode Details
Back to Episodes298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
Published 2 years, 7 months ago
Description
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.